Potential benefit of (-)-epigallocatechin-3-gallate for macrovascular complications in diabetes
Autor(a) principal: | |
---|---|
Data de Publicação: | 2017 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Brazilian Journal of Medical and Biological Research |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2017001000401 |
Resumo: | Vascular problems are the most common complications in diabetes. Substantial evidence from epidemiological and pathophysiological studies show that hyperglycemia is a major risk factor for macrovascular complications in patients with diabetes. (-)-Epigallocatechin-3-gallate (EGCG), the major catechin derived from green tea, is known to exert a variety of cardiovascular beneficial effects. The protective effects of EGCG in diabetes are also evident. However, whether EGCG is beneficial against macrovascular complications that occur in diabetes remains unknown. Our previous studies demonstrated that treatment of EGCG inhibits high glucose-induced vascular smooth muscle cell proliferation and suppresses high glucose-mediated vascular inflammation in human umbilical vein endothelial cells. Therefore, we hypothesize that EGCG might be an effective potential candidate to reduce the macrovascular complications in diabetes. |
id |
ABDC-1_8f0889802906c68ef856e6c59bca2df1 |
---|---|
oai_identifier_str |
oai:scielo:S0100-879X2017001000401 |
network_acronym_str |
ABDC-1 |
network_name_str |
Brazilian Journal of Medical and Biological Research |
repository_id_str |
|
spelling |
Potential benefit of (-)-epigallocatechin-3-gallate for macrovascular complications in diabetes(-)-Epigallocatechin-3-gallateDiabetesMacrovascular complicationsDiabetes complicationsHypothesisVascular problems are the most common complications in diabetes. Substantial evidence from epidemiological and pathophysiological studies show that hyperglycemia is a major risk factor for macrovascular complications in patients with diabetes. (-)-Epigallocatechin-3-gallate (EGCG), the major catechin derived from green tea, is known to exert a variety of cardiovascular beneficial effects. The protective effects of EGCG in diabetes are also evident. However, whether EGCG is beneficial against macrovascular complications that occur in diabetes remains unknown. Our previous studies demonstrated that treatment of EGCG inhibits high glucose-induced vascular smooth muscle cell proliferation and suppresses high glucose-mediated vascular inflammation in human umbilical vein endothelial cells. Therefore, we hypothesize that EGCG might be an effective potential candidate to reduce the macrovascular complications in diabetes.Associação Brasileira de Divulgação Científica2017-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2017001000401Brazilian Journal of Medical and Biological Research v.50 n.10 2017reponame:Brazilian Journal of Medical and Biological Researchinstname:Associação Brasileira de Divulgação Científica (ABDC)instacron:ABDC10.1590/1414-431x20176511info:eu-repo/semantics/openAccessTang,L.Li,L.Yang,J.Zeng,C.eng2019-03-19T00:00:00Zoai:scielo:S0100-879X2017001000401Revistahttps://www.bjournal.org/https://old.scielo.br/oai/scielo-oai.phpbjournal@terra.com.br||bjournal@terra.com.br1414-431X0100-879Xopendoar:2019-03-19T00:00Brazilian Journal of Medical and Biological Research - Associação Brasileira de Divulgação Científica (ABDC)false |
dc.title.none.fl_str_mv |
Potential benefit of (-)-epigallocatechin-3-gallate for macrovascular complications in diabetes |
title |
Potential benefit of (-)-epigallocatechin-3-gallate for macrovascular complications in diabetes |
spellingShingle |
Potential benefit of (-)-epigallocatechin-3-gallate for macrovascular complications in diabetes Tang,L. (-)-Epigallocatechin-3-gallate Diabetes Macrovascular complications Diabetes complications Hypothesis |
title_short |
Potential benefit of (-)-epigallocatechin-3-gallate for macrovascular complications in diabetes |
title_full |
Potential benefit of (-)-epigallocatechin-3-gallate for macrovascular complications in diabetes |
title_fullStr |
Potential benefit of (-)-epigallocatechin-3-gallate for macrovascular complications in diabetes |
title_full_unstemmed |
Potential benefit of (-)-epigallocatechin-3-gallate for macrovascular complications in diabetes |
title_sort |
Potential benefit of (-)-epigallocatechin-3-gallate for macrovascular complications in diabetes |
author |
Tang,L. |
author_facet |
Tang,L. Li,L. Yang,J. Zeng,C. |
author_role |
author |
author2 |
Li,L. Yang,J. Zeng,C. |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Tang,L. Li,L. Yang,J. Zeng,C. |
dc.subject.por.fl_str_mv |
(-)-Epigallocatechin-3-gallate Diabetes Macrovascular complications Diabetes complications Hypothesis |
topic |
(-)-Epigallocatechin-3-gallate Diabetes Macrovascular complications Diabetes complications Hypothesis |
description |
Vascular problems are the most common complications in diabetes. Substantial evidence from epidemiological and pathophysiological studies show that hyperglycemia is a major risk factor for macrovascular complications in patients with diabetes. (-)-Epigallocatechin-3-gallate (EGCG), the major catechin derived from green tea, is known to exert a variety of cardiovascular beneficial effects. The protective effects of EGCG in diabetes are also evident. However, whether EGCG is beneficial against macrovascular complications that occur in diabetes remains unknown. Our previous studies demonstrated that treatment of EGCG inhibits high glucose-induced vascular smooth muscle cell proliferation and suppresses high glucose-mediated vascular inflammation in human umbilical vein endothelial cells. Therefore, we hypothesize that EGCG might be an effective potential candidate to reduce the macrovascular complications in diabetes. |
publishDate |
2017 |
dc.date.none.fl_str_mv |
2017-01-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2017001000401 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2017001000401 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/1414-431x20176511 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Associação Brasileira de Divulgação Científica |
publisher.none.fl_str_mv |
Associação Brasileira de Divulgação Científica |
dc.source.none.fl_str_mv |
Brazilian Journal of Medical and Biological Research v.50 n.10 2017 reponame:Brazilian Journal of Medical and Biological Research instname:Associação Brasileira de Divulgação Científica (ABDC) instacron:ABDC |
instname_str |
Associação Brasileira de Divulgação Científica (ABDC) |
instacron_str |
ABDC |
institution |
ABDC |
reponame_str |
Brazilian Journal of Medical and Biological Research |
collection |
Brazilian Journal of Medical and Biological Research |
repository.name.fl_str_mv |
Brazilian Journal of Medical and Biological Research - Associação Brasileira de Divulgação Científica (ABDC) |
repository.mail.fl_str_mv |
bjournal@terra.com.br||bjournal@terra.com.br |
_version_ |
1754302945857372160 |